Navigation Links
Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
Date:8/19/2007

- Planning for Phase 3 Trial Initiation on Track -

BRISBANE, Australia, Aug. 16 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced it has executed an agreement with Quintiles, the world's largest Contract Research Organisation, to utilise their services for a number of clinical development- related projects. This agreement includes the execution of the Phase 3 clinical trial of anti-cancer drug PI-88 for the treatment of primary liver cancer (hepatocellular carcinoma).

Progen remains on track to initiate recruitment for the Phase 3 clinical trial in the fourth quarter of 2007. Quintiles operates directly in each of the 14 North American, European and Asian countries where Progen will be conducting the Phase 3 PI-88 trial.

"Quintiles has over 18,000 employees world-wide and has managed over 520 separate oncology studies. A number of these employees have been working with us as we prepare to initiate our Phase 3 trial in post-resection liver cancer. We have been consistently impressed with Quintiles's infrastructure in the regions where the trial will be conducted. They have already demonstrated to us that they have the communication and project management systems in place to successfully integrate key clinical operational procedures on the international level that this important trial requires," said Justus Homburg, Progen's CEO.

"Since the middle of last year, we have been working with external advisors, including Quintiles and the U.S. Food and Drug Administration (FDA), to develop our Phase 3 trial. We are aggressively pursuing the launch of this clinical trial on schedule and in parallel continue our discussions with the FDA on the SPA process," concluded Mr. Homburg.

The primary endpoint of the Phase 3 trial is the length of time patients remain disease-free (disease free survival or DFS) following surgery to remove tumour-affected parts of the liver. "Recent feedback f
'/>"/>

SOURCE Progen Pharmaceuticals Limited

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 STAAR Surgical Company ... and marketer of minimally invasive ophthalmic products, today announced ... to review the Company,s recent financial results and business ... Surgical will present at the 38 th Annual ... at the Westin Waterfront Hotel on Wednesday, ...
(Date:5/20/2013)... 2013  Volcano Corporation (NASDAQ: VOLC ) ... tools designed to enhance the diagnosis and treatment of ... highlight its efforts to expand research and innovation surrounding ... and iFR ® (Instant Wave-Free Ratio™) 1 ... at EuroPCR 2013 in Paris . ...
(Date:5/20/2013)... May 20, 2013 The Board of ... companies include OMNIlife science®, Inc., Enztec, Ltd., and Praxim, ... Board.  Guy Mayer , an ... of the Board of Directors and David Johnson, an ... director. Before joining OSI as Board ...
Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 2Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 3
... The Female Health Company (NASDAQ-CM: FHCO) today announced ... Comercio (Semina), was successful in a public tender to ... to 20 million FC2 Female Condoms.  The contract is ... will be determined at the Ministry of Health,s discretion. ...
... 6, 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... Financial Officer, August J. Moretti will present during the MDB ... Tuesday, May 10, 2011 at 10:00 a.m. Eastern Time.  The ... To access the presentation via the Web, please go ...
Cached Medicine Technology:The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3Alexza to Present at the MDB Bright Lights Conference 2011 2Alexza to Present at the MDB Bright Lights Conference 2011 3
(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud ... is the featured company in an impact report written ... “Adeptia Bets on Converged Cloud Integration and Process-Orchestration Suites,” ... products, pricing, customers and competition. , “For ... integration and process orchestration, especially when price, ease of ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... Grapefruits have long been known for their ... how medical therapies like anti-cancer drugs are delivered ... researchers have uncovered how to create nanoparticles using ... how to use them as drug delivery vehicles. ... Ph.D., and their team today (May 21, 2013), ...
(Date:5/21/2013)... May 21, 2013 Benefit Express Services, ... medium, and small organizations, will be hosting a free ... team from Findley Davies. The presentation will focus on ... in compliance with new Health Care Reform Requirements. The ... employees. , “Benefit Express regularly hosts free educational ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2
... and burying people who have died of HIV/AIDS in the ... living with the virus. ,"It is indeed shocking to ... dead body of a person who has died of HIV/AIDS ... the Mizoram People Living with HIV/AIDS Society, told IANS. ...
... by a whopping 25 percent annually to fetch India ... Minister Ambika Soni said Wednesday.// ,"The sector has ... foreign patients, we estimate that the country may fetch ... the "Incredible India: The Global Healthcare Destination" brochure. ...
... attack, New York City's Health Department yesterday issued long-awaited ... It comprises medical advice that is supposed to be ... scattered across the United States. ,The guidelines ... illness resulting from 9/11 experiences was previously given by ...
... cases in Africa as of last year hover around ... Nations //.The World Health Organization has suggested an intelligent ... ,The WHO has advised that the ... Africa could be used to give an impetus to ...
... Science (RIMS) here is battling for life after doctors gave her ... to RIMS for a surgery, received B+ blood instead of her ... next 48 hours are critical for her. ,She was ... ago. Her condition worsened when she was given the wrong blood, ...
... pill according to European researchers. The latest study supports ... allergen tablet.// Hay fever and other allergies have long ... result of the immune system reacting to a normally ... is supposed to enhance tolerance of the immune system ...
Cached Medicine News:Health News:Strange Burial Practice Followed for People Affected by HIV/AIDS 2Health News:Medical Tourism can Fetch Rs.100 bn Annually by 2012 2Health News:Medical Tourism can Fetch Rs.100 bn Annually by 2012 3Health News:Medical Guidelines to treat 9/11-related illness 2
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
... is a quick and effective means to seal ... tubes. The compliant inner layer is designed to ... minimizes the risk of aerosol formation and cross-contamination ... use with fewer than 96 wells, and a ...
OptiTape individual sheets. Optically clear sealing tape for OmniUltra PCR plates. 100 pk....
OptiTape - Optically Clear sealing tape for OmniUltra PCR plates plus universal dispenser. 250 sheets....
Medicine Products: